Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatinib. However, questions remain unanswered regarding the biological basis of molecular relapse after imatinib c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rea, Delphine, Henry, Guylaine, Khaznadar, Zena, Etienne, Gabriel, Guilhot, François, Nicolini, Franck, Guilhot, Joelle, Rousselot, Philippe, Huguet, Françoise, Legros, Laurence, Gardembas, Martine, Dubruille, Viviane, Guerci-Bresler, Agnès, Charbonnier, Aude, Maloisel, Frédéric, Ianotto, Jean-Christophe, Villemagne, Bruno, Mahon, François-Xavier, Moins-Teisserenc, Hélène, Dulphy, Nicolas, Toubert, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643734/
https://www.ncbi.nlm.nih.gov/pubmed/28522576
http://dx.doi.org/10.3324/haematol.2017.165001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643734/
https://www.ncbi.nlm.nih.gov/pubmed/28522576
http://dx.doi.org/10.3324/haematol.2017.165001

Ejemplares similares